Neurogene (NGNE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Voting matters and shareholder proposals
Election of Class III Directors for terms expiring in 2029, with nominees Robert Baffi, Ph.D. and Rohan Palekar recommended for election.
Advisory (non-binding) vote to approve the compensation of named executive officers.
Advisory (non-binding) vote to ratify Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote on the frequency of future say-on-pay votes, with a recommendation for every one year.
Proxies are authorized to vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends the election of two Class III Directors for five-year terms expiring in 2029.
Executive compensation and say-on-pay
Advisory vote proposed to approve the compensation of named executive officers.
Shareholders to vote on the frequency of future say-on-pay votes, with a one-year interval recommended.
Latest events from Neurogene
- NGN-401 shows robust, durable efficacy and safety, advancing toward commercialization for Rett syndrome.NGNE
Corporate presentation - NGN-401 showed robust efficacy and safety, with cash runway into Q1 2029.NGNE
Q2 2026 - NGN-401's pivotal study nears completion, with 12-month data and US commercialization on track for 2026.NGNE
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - NGN-401 gene therapy enabled rapid, durable, multidomain gains with strong safety in Rett syndrome.NGNE
Study result - All proposals passed, directors elected, and no shareholder questions or proposals submitted.NGNE
AGM 2026 - NGN-401 shows durable, multidomain benefits in Rett syndrome, with pivotal trial and launch prep underway.NGNE
Corporate presentation - NGN-401 Embolden trial dosing nears completion; strong cash runway and interim data expected mid-2026.NGNE
Q1 2026 - NGN-401 shows sustained, multi-domain gains in Rett syndrome with high responder rates and robust safety.NGNE
TD Cowen 46th Annual Health Care Conference - Board recommends approval of all proposals, with detailed governance and compensation disclosures.NGNE
Proxy filing